Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics Chief Business Officer Gary Charles Robb reported a Form 4 showing a bona fide gift of 600 shares of Corcept Therapeutics common stock on May 27, 2026. The gift carried no sale price. After this transfer, he directly holds 25,081 shares of common stock. He also indirectly holds shares through a revocable trust with 49,716 shares and through two custodial accounts for children, each with 12,571 shares. Footnotes note additional unvested restricted stock awards scheduled to vest on the one-year anniversaries of their respective grant dates, subject to service conditions.
Corcept Therapeutics Chief Development Officer William Guyer reported a combination of option exercises and stock sales in Corcept Therapeutics common stock. He exercised stock options covering 20,000 shares at an exercise price of $21.65 per share, then sold a total of 20,000 shares in open-market transactions at weighted average prices of $93.11 and $93.54, all under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he holds 4,937 common shares directly, plus 130,000 stock options and unvested restricted stock awards that vest on their one-year anniversaries if conditions are met.
William Guyer filed a Form 144 to sell 20,000 shares of common stock via a stock option exercise on 07/07/2026. The notice lists the sale method as Cash through Stifel Nicolaus & Company, Inc. The filing also discloses three sales in the prior three months: 20,000 shares on 04/07/2026 for $819,453, 20,000 shares on 05/05/2026 for $1,036,522, and 20,000 shares on 06/02/2026 for $1,411,993.
Corcept Therapeutics executive Sean Maduck reported option exercises and stock sales. He exercised stock options to acquire 25,000 shares of Common Stock at a strike price of $8.27 per share and sold 25,000 shares in multiple open‑market transactions at weighted average prices around $87–$89 per share under a Rule 10b5-1 trading plan adopted on December 8, 2025.
Following these transactions, he held 9,755 Common shares directly and 116,986 stock options directly, and also reported indirect holdings through trusts and LLCs, some of which he serves as trustee, co‑trustee, member, manager, or president. The filing also notes several unvested restricted stock awards that vest one year after their respective 2025–2026 grant dates if conditions are met.
Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, sold 10,000 shares of Common Stock on June 16, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026. The shares were sold at weighted average prices of $83.5708 and $82.6948 per share, with actual prices ranging from $82.13 to $83.935 per share. Following these sales, the trust continues to hold more than 1.09 million shares according to the filing, while two separate 2025 Grantor Retained Annuity Trusts each report indirect holdings of 200,000 shares. Wilson disclaims beneficial ownership of the trust shares except to the extent of his pecuniary interest.
Corcept Therapeutics director David L. Mahoney reported an indirect open-market sale of common stock through The Black Dog Private Foundation. The foundation sold 20,000 shares at a weighted average price of $84.5253 per share, with individual prices ranging from $84.44 to $85.11.
After the sale, the foundation held 26,147 shares of Corcept common stock. A separate indirect holding, the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, is shown with 1,237,145 shares of common stock following the reported transactions.
Corcept Therapeutics has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. The resubmission includes additional analyses of data from prior studies, as requested by the FDA, and is expected to receive a six-month review.
The filing highlights positive results from Corcept’s GRACE and Phase III GRADIENT trials, a long-term extension study and earlier-stage data, which the company believes show meaningful, durable improvements in Cushing’s symptoms without some serious side effects seen with existing therapies. Relacorilant already holds orphan drug designations and is approved as Lifyorli for platinum-resistant ovarian cancer.
Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock. He exercised stock options covering 40,000 shares at an exercise price of $19.26 per share, then sold 40,000 shares in multiple open-market transactions at weighted average prices between approximately $79.40 and $82.18 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 16,130 common shares, which include shares underlying several unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.
The Charles Schwab Corporation provided a Form 144 notice related to proposed transactions in Common stock. The filing lists 20,000, 1,666,800.00, and 107,351,594 as numeric entries and references 06/16/2026 and NASDAQ.